Drug Approval | April 26, 2022
USFDA approves first Covid-19 treatment for young children
This action makes Veklury the first approved Covid-19 treatment for children less than 12 years of age
This action makes Veklury the first approved Covid-19 treatment for children less than 12 years of age
A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme
In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)
Designed to give instant insights on blood sugar, in-depth nutrition and wellness, this programme provides fitness assessments, personalisation and reports for doctors
Peak Proteins has collaborated closely with Sygnature Discovery for several years and together the companies have supported a number of integrated drug discovery programmes
Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers
Covaxin was earlier approved for children 12-18 years of age
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics
The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation
Subscribe To Our Newsletter & Stay Updated
